Drugs / MONARSEN
MONARSEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01506362 | Mar 2012 → May 2013 | ulcerative colitis | BioLineRx, Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2013-11-26 | BioLineRx, Ltd. | Results BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment biolinerx.com ↗ |
| 2013-04-17 | BioLineRx, Ltd. | Results BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease biolinerx.com ↗
BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease (IBD). |
| 2012-03-05 | BioLineRx, Ltd. | Regulatory BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease biolinerx.com ↗
BioLineRx (NASDAQ:BLRX; TASE:BLRX) a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD). |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MONARSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068601 ↗ |
| Known as | 0dn-7040 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068601 ↗ |
| Known as | BL-7040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01506362 ↗ |
| Known as | EN-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068601 ↗ |
| Modality | Oligonucleotide (other) | “BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.” NCT01506362 ↗ |
| Route | Oral | “BL-7040 is an orally available new chemical entity for the treatment of IBD.” NCT01506362 ↗ |